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The seronegative spondyloarthropathies, including psoriatic
arthritis (PsA) and ankylosing spondylitis (AS), are characterized by
varied clinical symptoms, severity, and disease course [1,2]. Diagnosis
and monitoring can be challenging because there is no deﬁnitive lab-
oratory biomarker for reliably measuring inﬂammation or other dis-
ease processes associated with spondyloarthropathies. Over time,
many patients with PsA and AS eventually experience signiﬁcant dis-
ability and impaired quality of life [1,2]. This may be partiallyAbbreviations: AS, ankylosing spondylitis; EPIC, Epidemiology of Psoriatic Arthritis;
HLA, human leukocyte antigen; IL, interleukin; MHC, major histocompatibility com-
plex; IMAPA, Immune Metabolic Associations in Psoriatic Arthritis; MRI, magnetic res-
onance imaging; MRM, multiple reaction monitoring; NIHR, National Institute for
Health Research; PDUS, power Doppler ultrasound; PEER, Platform for the Exchange of
Expertise and Research; PROMISE, PROgnostic Markers In Spondyloarthritis; PROMPT,
“early detection to imPRove OutcoMe in people with undiagnosed Psoriatic arthriTis”;
PsA, psoriatic arthritis; RA, rheumatoid arthritis; SMI, superb microvascular imaging;
SpA, spondyloarthritis; SPADE, Spondyloarthritis Diagnosis Evaluation; TNF, tumor
necrosis factor; TUDOR, Total bUrDen of psoriasis.
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well as the presence of comorbidities.
In recent years, research efforts aimed at identifying risk factors
for PsA, including clinical, imaging, genetic, and laboratory assess-
ments, have yielded major advances. The Platform for the Exchange
of Expertise and Research (PEER) was formed to facilitate the
exchange of research insights, sharing of expertise, and discussion of
unmet needs in rheumatology research.
The objective of the current report is to provide an overview of the
2017 PEER meeting, which was held on May 1920, 2017, in London,
UK, and highlighted the most up-to-date research ﬁndings regarding
PsA and AS pathophysiology, early detection, comorbidities, and
treatment.Development of psoriatic arthritis in patients with psoriasis:
insights from a prospective cohort Dr. Lihi Eder
The majority of patients with PsA initially develop skin disease,
with joint disease following approximately 713 years later [4,5]. A
delayed diagnosis of PsA is associated with worse outcomes than
when the diagnosis is made earlier in the disease course [3]. In order
to identify patients at risk for PsA, and increase early diagnosis andr the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
1006 S. Abraham et al. / Seminars in Arthritis and Rheumatism 48 (2019) 10051013treatment, the ongoing Toronto Psoriasis Cohort Study aims to evalu-
ate the genetic and environmental risk factors associated with PsA
development; enrolled patients with psoriasis are followed on a
yearly basis until they develop PsA (Fig. 1) [6].
The study has suggested that the incidence of PsA is higher than pre-
viously estimated [6]. Based on the data collected, a prediction model
estimated that over 20 years of follow-up, approximately 35% of the
cohort patients were predicted to develop PsA [6]; this contrasts with
only 5% cumulative prevalence among psoriasis patients described in a
previous report of a Rochester, Minnesota, cohort [7]. In the Toronto
Psoriasis Cohort Study, clinical factors (including psoriasis severity),
presence of nail lesions or uveitis, lower level of patient education, and
use of retinoids to treat psoriasis were predictors of PsA development
[6,8]. A related body of research has also identiﬁed trauma as a signiﬁ-
cant predictor of PsA development [911]. By contrast, trauma is not
associated with onset of rheumatoid arthritis (RA) [9].
Other factors associated with PsA development in the Toronto cohort
as well as a UK cohort include higher bodymass index; presence of non-
speciﬁc musculoskeletal symptoms, including pain, fatigue, and stiffness,
among psoriasis patients, even in the absence of distinct arthritis on
physical examination; and certain biomarkers [6,12]. C-X-C motif che-
mokine 10 (CXCL10) was found at higher levels in the serum of patients
with psoriasis who subsequently developed PsA and may be a potential
biomarker for predicting PsA [13,14]. Subclinical enthesitis, as detected
by magnetic resonance imaging (MRI) or ultrasound, is often present in
patients with psoriasis and observed at the nail and joints; the clinical
signiﬁcance of this ﬁnding requires further investigation [8,15].
Overall, the ﬁndings derived from the Toronto cohort and other
related investigations indicate that it may be possible to identify a
subset of psoriasis patients who may be at higher risk for the devel-
opment of PsA than other psoriasis patients. Based on the Toronto
cohort analyses discussed above, PsA risk factors include trauma,
higher body mass index, severe skin psoriasis, nail lesions, uveitis,
and nonspeciﬁc musculoskeletal symptoms, as well as higher serum
levels of CXCL10. Use of these ﬁndings in the clinic may give rise to a
new model of care in which certain psoriasis patients ﬂagged as at
high risk for PsA could obtain treatment at a substantially earlier
stage of PsA disease development. Prompt identiﬁcation of risk fac-
tors for PsA and earlier treatment initiation could potentially prevent
the development of full-blown PsA.PROMPT research program: an overview and update ‒ Professor
Neil Mchugh
The ongoing UK National Institute for Health Research (NIHR)-
funded program grant for applied research, “early detection toFig. 1. The pre-clinical phases of PsA [6]. MSK, musculoskeletal psoriatic arthritis. Risk facto
spective observational study assessing the development of psoriatic arthritis in patients withimPRove OutcoMe in people with undiagnosed Psoriatic arthriTis”
(PROMPT), encompasses a series of research activities aimed at facili-
tating accurate and early detection of PsA in UK primary care. An
additional aim of the study is to develop patient-completed outcome
measures of early disease that are relevant to patients with PsA and
not adequately captured by currently available assessments.
The PROMPT research program includes focus groups examining
what patients perceive to be important patient-reported outcome
measures to enhance early screening, detection, and diagnosis in the
primary care setting and in clinical treatment of PsA [16,17]. PROMPT
draws upon ﬁndings from the ongoing Epidemiology of Psoriatic
Arthritis (EPIC) study, which is based on analysis of the Clinical Prac-
tice Research Datalink database for epidemiological factors associated
with PsA. It also encompasses ongoing research into cost-effective-
ness, screening questionnaires, and barriers to PsA diagnosis.
To date, focus group studies have demonstrated that pain and
fatigue are rated as most important by patients, yet neither of these
conditions is adequately captured in current composite measures for
PsA [16,17]. Moreover, a substantial proportion of patients are diag-
nosed with PsA within 13 years of the onset of cutaneous psoriasis
[5]. The interval between onset of psoriasis and PsA appears to have a
genetic basis, with human leukocyte antigen (HLA)-C*06 being asso-
ciated with a prolonged delay in PsA development and HLA-B*27
being associated with very short interval or contemporaneous onset
of psoriasis and PsA [18,19]. The PROMPT study further indicated that
uveitis and Crohn's disease, but not ulcerative colitis, are more com-
mon in patients with PsA than in those with psoriasis alone [20]. The
Total bUrDen of psORiasis (TUDOR), an ongoing randomized, con-
trolled study, is central to PROMPT in evaluating enhanced surveil-
lance of PsA compared with standard primary care. TUDOR is the ﬁrst
study to prospectively examine the impact of early diagnosis on long-
term outcomes in PsA (Fig. 2); with a planned 5-year duration, out-
comes are expected to become available in 2021.The ongoing quest for early diagnosis and biomarker discovery in
ankylosing spondylitis ‒ Dr. Raj Sengupta
Goals for improving outcomes in AS include earlier detection and
treatment, which represents a major challenge and unmet need. In
1999, the time between symptom onset and diagnosis was a median
of 5 years, which had not improved in 2013, based on analysis of clin-
ical data at 2 large UK secondary care centers [21].
As with PsA, delay in diagnosis is associated with worse outcomes,
including poor function and mobility and increased risk of work dis-
ability [22,23]. When AS is diagnosed and treated earlier, the Bath
Ankylosing Spondylitis Metrology Index score tends to bers shown are based on data from the Toronto Psoriasis Cohort Study, a long-term pro-
psoriasis.
Fig. 2. Overview of the PROMPT investigative plan. CPRD, UK Clinical Practice Research Datalink; PROMPT, “early detection to imPRove OutcoMe in people with undiagnosed Psori-
atic arthriTis”; PROMS, patient-reported outcome measure; RCT, randomized controlled trial.
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not deteriorate [24]. In 1 study, a higher proportion of patients with
early disease (< 5 years) responded to adalimumab treatment com-
pared with patients with later disease ( 5 years) [25]. Another study
demonstrated that following initiation of tumor necrosis factor (TNF)
inhibitor treatment, radiographic progression was signiﬁcantly
slower in early disease patients than in later disease patients [26].
Among the emerging biomarkers for early detection of AS are
approximately 41 genes, including those that encode major histo-
compatibility complex (MHC) class 1 proteins; related genes such as
ERAP1, UBE2E3, UBE2L3, and those involved in CD8 + T-cell function;
microbial sensing genes; and those involved in other immune func-
tions that are not clearly understood [27,28]. However, the usefulness
of these biomarkers in the clinical setting is not yet well developed.
Other inﬂammatory markers, such as C-reactive protein, erythro-
cyte sedimentation rate, and vascular endothelial growth factor, are
not sufﬁciently speciﬁc and sensitive to differentiate patients with AS
from either healthy controls or those with other arthropathy. Some
patients with AS may exhibit normal values, and elevations of these
markers are seen in other arthropathies [29,30]. IL-17 and IL-23, how-
ever, have been found to be more consistently elevated in patients
with AS compared with healthy controls [31]. Markers of bone turn-
over, such as Wnt-3a, sclerostin, monocyte chemoattractant protein-
1, and calprotectin, are promising because they tend to be higher in
patients with AS compared with healthy controls [30,32,33]. Among
these, only monocyte chemoattractant-1 has demonstrated the capa-
bility to distinguish AS patients from healthy controls or those with
mechanical low back pain [33]. Likewise, while anti-ﬂagellin antibod-
ies and diagnostic biomarkers (e.g., autoantibodies against protein
phosphatase magnesium-dependent 1A) are also elevated in patients
with AS, only autoantibodies against protein phosphatase magne-
sium-dependent 1A have shown promise in helping to distinguish
between patients with AS vs. healthy controls or patients with RA or
PsA, given that they correlate with baseline disease severity and vary
according to changes in disease severity related to clinical response
to TNF-a inhibitor treatment [34,35]. These ﬁndings, however,
require further validation in an independent patient cohort.
Major challenges in the use of biomarkers for AS diagnosis include
a lack of consistent results across studies, large variation among
patients due to the heterogeneous nature of AS, and questions around
the reliability of the assays. Large studies in well-deﬁned patientcohorts are needed to bring use of these biomarkers to the bedside.
To address some of these challenges, the PROgnostic Markers In
Spondyloarthritis (PROMISE) study is under way, with a planned
enrollment to include 250 patients with axial SpA or AS, with assess-
ments to identify prognostic markers in SpA, including patient-
reported outcomes and radiograph, MRI, biomarker, and genetic anal-
yses. In the meantime, Web-based tools aimed at healthcare pro-
viders and patients with the intention of improving early AS
detection are available, including the Spondyloarthritis Diagnosis
Evaluation (SPADE) tool for the global provider community (http://
www.spadetool.co.uk/), Back in Focus website for primary general
practitioners (https://www.axialspabackinfocus.co.uk, sponsored by
AbbVie), and Don't Turn Your Back on It website for patients (http://
www.dontturnyourbackonit.co.uk).Subclinical enthesopathy and development of psoriatic arthritis ‒
Professor Dennis McGonagle
Enthesitis is inﬂammation occurring in tissue that connects ligament
to bone, driving cytokine-mediated immunobiologic response at sites in
the body that otherwise lack an immune response [36]. It is a common
hallmark of the spondyloarthropathies, including PsA and AS [36]. Ongo-
ing work has revealed how both mechanical stress and the genes
responsible for the interleukin (IL)-12 and IL-23 inﬂammatory pathway
have been associated with the development of enthesitis [37].
In murine models of spondyloarthritis (SpA), entheseal-resident
IL-23 receptor-positive T cells have been shown to be critical to SpA
pathogenesis [37]. In human entheseal tissue, IL-23R-positive innate
type 3 lymphoid cells are present and show elevated levels of trans-
forming growth factor-b1 and TNF-a transcripts [38]. Moreover,
patients with SpA and PsA exhibit microdamage at ligament and ten-
don attachment sites associated with MHC type 1-linked signals,
including HLA-B*27 [39,40]. Clinically asymptomatic patients often
have enthesopathy observed on ultrasound [41,42] and preliminary
studies have shown that the presence of subclinical enthesitis may
predict the development of PsA [43]. Enthesopathy is also linked to
nail disease, which in turn is linked to PsA development [7,44]. In
patients with psoriasis, barrier dysfunction may contribute to adap-
tive MHC-1-associated immune responses that drive enthesopathy
and PsA development (Fig. 3) [45].
Fig. 3. Enthesopathy in psoriasis: Adaptive immune priming [45]. DAMP, damage‑associated molecular pattern; DC, dendritic cell; ERAP1, endoplasmic reticulum aminopeptidase 1;
NK, natural killer cell; PAMP, pathogen‑associatedmolecular pattern.
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the anti-TNFs, and ustekinumab [46], as well as anti-IL-17s and apre-
milast, may help to resolve subclinical enthesitis because these agents
also have licensed indications for treating clinical arthritis. In a study
using methotrexate (with or without a concomitant TNF inhibitor) in
patients with psoriasis or PsA, the number of entheses with inﬂam-
matory abnormalities based on ultrasound was signiﬁcantly
decreased with 6 months of treatment [46]. The enthesis may be use-
ful for ultrasound screening for early or preclinical PsA, as well as a
treatment target; likewise, the systemic treatment of psoriasis has
the potential to prevent development of arthritic lesions [43,46].
Superb microvascular imaging: novel Doppler ultrasound
technology and its application in rheumatic diseases ‒ Professor
Adrian Lim
With the availability of new imaging techniques, the potential exists
to diagnose PsA earlier and to better understand disease progression.
Well-established imaging techniques that have been used to assess vas-
cular ﬂow include color/power Doppler ultrasound (PDUS) and some
advanced dynamic ﬂow ultrasound technologies. PDUS is cost-effective
compared with contrast-enhanced MRI and useful for assessing inﬂam-
mation in joints or tendons [47,48]. It is the current accepted gold stan-
dard to denote active inﬂammation in joints and tendons.
Superb microvascular imaging (SMI) is an emerging and novel ultra-
sound technology that allows visualization of the microvasculatureFig. 4. Superb microvascular imaging of the indewithout the need for ultrasound contrast. SMI uses ﬁlters and a unique
algorithm to selectively detect and remove random clutter without
compromising the clinical data of interest. SMI, utilizing 24MHz power,
can distinguish slower ﬂowing vessels within the microvasculature,
which may help to identify sites of active inﬂammation (Fig. 4). In a
study directly comparing the ability of SMI to detect inﬂammation in
tendons and joints vs. PDUS, SMI revealed vascularity that was not
detected by PDUS in a signiﬁcant number of cases (P = 0.007); in cases
where vascularity was detected by both PDUS and SMI, vascularity
scores were signiﬁcantly greater with SMI (P< 0.001) [49].
Three-dimensional ultrasound imaging is also on the horizon. While
the technology is available, its use requires training on how to properly
manipulate the images. Images are currently of low resolution; how-
ever, algorithms are improving. Three-dimensional ultrasound has
potential uses in measuring and quantifying vascularity in combination
with SMI, as well as imaging cartilaginous surfaces. In addition to its
potential usefulness in screening and diagnosis, future studies may
include SMI to measure changes in vascularity during treatment.
Psoriatic arthritis and immune-metabolic interactions ‒ Dr. Stefan
Siebert
PsA is associated with comorbid diabetes, hypertension, and car-
diovascular disease, as well as hyperuricemia [50,51]. Accumulating
evidence demonstrates that metabolic dysfunction underlying these
comorbid conditions is a key component of the PsA disease processx ﬁnger in a patient with psoriatic arthritis.
Fig. 5. Targeting PDE4 suppresses inﬂammation and decreases adiposity. Reprinted with permission fromWu C and Rajagopalan S. Phosphodiesterase-4 inhibition as a therapeutic
strategy for metabolic disorders. Obes Rev 2016;17:429-41 [58],  JohnWiley and Sons. cAMP, cyclic adenosine monophosphate; PDE4, phosphodiesterase 4.
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PsA are more likely to have metabolic syndrome, as well as a greater
number of metabolic syndrome components, than patients with RA
or other, non-inﬂammatory conditions [5254].
PsA patients also are more likely to be obese than the general pop-
ulation and to have a higher body mass index than patients with RA
[52,55]. Additionally, psoriasis patients who are overweight or obese
are more likely to develop PsA [55,56]. Obesity may play a role in the
development of PsA and may inﬂuence treatment response. The
release of adipokines from fat cells can drive metabolic dysfunction
as well as pro-inﬂammatory pathways (Fig. 5), potentially leading to
increased PsA risk [57,58]. Obesity is also associated with decreasing
likelihood of optimal clinical response to therapy in PsA [59,60], while
weight loss is associated with increased likelihood of achieving good
outcomes with TNF inhibitor therapy [61].
The metabolic component of PsA may be inﬂuenced by the treat-
ment prescribed. One study showed that PsA and RA patients who
were receiving TNF inhibitors or hydroxychloroquine were at lower
risk for developing diabetes than patients who were receiving metho-
trexate [62]. However, certain disease-modifying anti-rheumatic
drugs, including TNF inhibitors, are associated with weight gain or an
increase in percentage of body fat [63,64]. Phosphodiesterase 4 inhib-
itors have been associated with weight loss as well as reduction in
hemoglobin A1c and may decrease insulin resistance [58,6567]
(Fig. 5). The ongoing Immune Metabolic Associations in Psoriatic
Arthritis (IMAPA) study in Glasgow, UK, is investigating the effects of
phosphodieasterase 4 inhibition on immune-metabolic interactions
in PsA using the phosphodiesterase 4 inhibitor apremilast (Clinical-
Trials.gov identiﬁer: NCT03399708).
New insights into the genetics of psoriatic arthritis ‒ Professor
Anne Barton
PsA is a complex disease that has environmental and strong
genetic components that contribute to susceptibility [68]. Identifying
PsA susceptibility genes can aid in predicting disease development,helping to indicate suitable preventive strategies, as well as in the
design of more targeted drug therapies. In a genome-wide association
study, variants of the TRAF3IP2 gene were associated with PsA and
psoriasis [69]. In a more recent case-control association analysis,
while PsA-associated loci exhibited extensive overlap with known
psoriasis-susceptibility loci, the 5q31 locus was speciﬁc to PsA [70].
Within the 5q31 locus, ﬁne mapping analysis of single nucleotide
polymorphisms revealed SLC22A5 to be a likely candidate causal gene
associated with PsA, with rs715285 or rs10065787 being the possible
causal variant [70]. This association is independent of the IL-13 asso-
ciation with psoriasis.
Another gene known to be very important in the development of
psoriasis and PsA encodes the IL-23 receptor (IL-23R) [70]. However,
distinctly different variants on the IL-23R gene are associated with
psoriasis vs. PsA; the gene associated with psoriasis encodes a non-
synonymous variant and may impact gene function, while the PsA-
associated variant is located in the IL-23R promoter region and may
impact gene expression, although that has yet to be experimentally
conﬁrmed (Fig. 6) [71].
Variants linked to PsA appear more often to co-localize with epi-
genetic markers of open chromatin in CD8 +memory T cells. Genes
encoding HLA subtypes have been strongly associated with psoriasis
and PsA [70]. HLA-C*0602 is strongly associated with both conditions
and yet it counterintuitively has been reported to be protective for
PsA compared with psoriasis [70,72]. However, after controlling for
age at onset of psoriasis, HLA-C*0602 has been shown to be primarily
associated with skin (psoriasis) rather than joint (PsA) disease [73].
By contrast, variants at HLA-B (amino acid position 97) are associated
with PsA and AS. The speciﬁc amino acid residue at position 97 may
mediate which disease develops, and individuals with an associated
serine residue are at risk for PsA but not for AS; those with an associ-
ated asparagine residue are at risk for both PsA and AS [73,74].
While an extensive overlap has been seen among the genes asso-
ciated with psoriasis and PsA, a distinct set of genes uniquely contrib-
ute to the risk of PsA. Ongoing work encompassing genome-wide
association studies, analysis of rare gene variants, and analyses of
Fig. 6. Different IL-23R gene variants are associated with PsA vs. psoriasis [71]. PsA, psoriatic arthritis; SNP, single nucleotide polymorphism.
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pitting, uveitis, and severe psoriasis, are required to fully understand
the genetic background to PsA.Arthropathies under a proteomic spotlight ‒ Professor Stephen
Pennington
The entire set of proteins expressed by an organism or an organ
system may be evaluated using mass spectrometry-based proteomics
[75]. In an era of increased understanding of disease complexity, such
a proteomic approach forms the cornerstone of studies into the iden-
tiﬁcation and measurement of panels of protein biomarkers that cor-
relate with presence or severity of a certain condition [76,77]. Such
protein biomarker panels or signatures may be used to improve dis-
ease diagnosis or treatment and to better support personalized medi-
cine. This approach and process (using antibody-based assays) has
yielded some success in the setting of RA, with approval and clinical
adoption of the Vectra

DA test (Crescendo Bioscience, Inc., South San
Francisco, CA, USA), which examines 12 biomarkers associated with
RA disease activity [78].
For rheumatic diseases such as PsA and AS, a wide variety of treat-
ments are available; however, only a small proportion of patients
respond to any single treatment. Because rheumatic diseases are so
physiologically heterogeneous, systems-driven proteomics may be a
valuable approach toward predicting patient response to treatment
by allowing personalized treatment decisions based on a unique pro-
ﬁle or signature of proteins detected in a patient's tissue, synovial
ﬂuid, or blood [7981]. Ongoing proteomic projects in PsA include
examination of the pathophysiologic role of the IL-17 receptor and its
adaptor protein ACT-1, biomarkers that predict response to TNF
inhibitor treatment, biomarkers that predict joint damage, and bio-
markers that aid PsA diagnosis [8286].
The proteomic strategy begins with unbiased protein discovery,
followed by assay development. The use of multiple reaction moni-
toring (MRM) mass spectrometry for multi-protein assays supports
rapid assay development and analytical validation. Following clinical
evaluation, the assays are then subjected to regulatory approval and
adoption in the clinical setting (Fig. 7).
With regard to developing a similar test for PsA, several key ques-
tions remain unanswered. We do not fully understand the biologic
mechanisms underlying bony changes that occur in PsA. Moreover,
no biomarker test clearly differentiates PsA from RA, and no knownpredictors have been linked to response to a given treatment. To
address these challenges, the ongoing Health Research Board (Ire-
land)-funded study (PAPRICA) aims to evaluate approximately 140
target candidate proteins considered to be involved in PsA patho-
physiology using MRM assays on blood samples obtained from
patients enrolled in a number of clinical studies. It is hoped that the
impending ﬁndings may be calibrated to address a variety of clinical
questions and issues, including differential PsA/RA diagnosis, predict-
ing disease progression or prognosis, and predicting treatment
response.Genetics and immunology of ankylosing spondylitis ‒ Professor
Paul Bowness
AS and the related spondyloarthritides are a group of diseases that
share common genetic and clinical features, including inﬂammation
that involves IL-23- and IL-17-driven signaling, enthesitis, and new
bone formation [87]. Phenotypically, SpA and AS are considered
immune-mediated inﬂammatory diseases, somewhere on a spectrum
between autoimmune diseases and autoinﬂammatory diseases. AS is
associated with a major hereditary component; the presence of HLA-
B*27 accounts for approximately 30% of the hereditary variation,
while ERAP1, IL-23R, IL-12B, and other genes linked to Th17 responses
play lesser roles (> 100 loci have been linked to AS in large genetic
analyses) [87,88].
HLA-B*27 is an MHC class 1 molecule that is present on most cells
of the body. It functions by presenting peptide antigens to CD8+ T
cells [87]. Each HLA-B*27 molecule carries a speciﬁc peptide antigen
and is capable of initiating a corresponding immune response. The
role of HLA-B*27 in AS pathogenesis is not completely understood;
however, several hypotheses (i.e., arthritogenic, unfolded protein
response, and free heavy chain) are being studied (Fig. 8). According
to the arthritogenic hypothesis, HLA-B*27 might present “arthrito-
genic” peptides (e.g., from joints) to CD8 + T cells, hence triggering
inﬂammation [87]. Alternatively, the unfolded protein response
hypothesis proposes that inappropriate HLA-B*27 folding or trafﬁck-
ing might also occur due to malfunctioning ERAP1, which normally
acts to trim the peptides bound to HLA-B*27 molecules and therefore
facilitates cell surface egress [87]. The free heavy chain hypothesis
posits that HLA-B*27 might malfunction due to the presence of an
unpaired cysteine residue at position 67, which can cause it to form
homodimers by pairing with another HLA-B*27 residue. HLA-B*27
Fig. 7. Multiple reaction monitoring development. LC-MS/MS, liquid chromatographymass spectrometry.
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cell surface, where they can then bind to several immune receptors,
triggering aberrant immune responses, including Th17 responses
[87]. Th17 cells in turn produce a number of ILs, including IL-17, IL-
21, IL-22, and IL-23. CD4 cells, including Th17 cells that express the
KIR3DL2 receptor, which can bind strongly to HLA-B*27 homodimers,
are increased in patients with AS and are increased in the joints of
patients with SpA [89]. Currently, immunotherapy for AS includes
TNF inhibitors and biologic therapies targeting IL-17/23. Future treat-
ments may include small molecule inhibitors that target components
of the Th17 inﬂammatory responses, such as HLA-B*27 signaling,
transcription factors, and ERAP1.
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